GENE ONLINE|News &
Opinion
Blog

Gene Editing
Moderna, Life Edit To Develop In Vivo Gene Editing Therapies
2023-02-23
Treating Common Heart Disease with CRISPR-Cas9 Gene Editing
2022-12-27
Verve and Vertex Agree to Co-Develop In Vivo Gene Editing Program for Liver Disease
2022-07-21
Verve Cleared to Test Gene Editing Drug for Heart Disease in Humans
2022-05-12
TALED Tool Launches a New Era of Mitochondrial Genome Editing
2022-05-03
CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label
2022-04-27
FDA Announces Draft Guidances on Genome Editing and CAR T Cell Therapy
2022-03-25
China Pushes for Faster Approval for Gene-Edited Crops
2022-02-15
What If Our Body’s Power Station Goes Wrong? Gene Therapy May Help
2022-02-15
GeneOnline’s Pick: Novel Biotechnologies that Made a Splash in 2021
2022-01-27
GeneOnline’s Top 10 Editor’s Picks for 2021
2021-12-23
Harnessing the potential of CRISPR-Cas9 for Gut Microbiome Gene Editing
2021-11-29
Study Advocates Cautious Application of CRISPR in Designing Therapeutics
2021-11-22
Chroma Medicine Debuts with High Hopes for “Game-Changing” Epigenetic Genome Editors
2021-11-17
Moderna Enters Gene Editing Market with Metagenomi Collaboration
2021-11-03
1 2 3 6
LATEST
Big Pharma’s Next Move: BMS, Merck, Amgen Eye M&A to Tackle Patent Expirations
2024-11-14
Taiwan and Australia Bridge Biotech Frontiers and Strengthen Ties at AusBiotech 2024
2024-11-14
Google DeepMind Open-Sources AlphaFold 3: A Game-Changer for Drug Discovery and Biotech
2024-11-12
Hiroaki Ueno: Leading Japan’s Pharma Revolution with Innovation and Global Strategy
2024-11-12
Japan’s Bio-Economy Push: A Future Driven by Innovation and Global Collaboration
2024-11-12
Opening the Door to ‘Designer Babies’? South Africa’s Genome Editing Guidelines Spark Global Debate
2024-11-08
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
2024-11-08
EVENT
2024-12-05
8th Healthcare Expo Taiwan
Taipei, Taiwan
Scroll to Top